iRadimed
IRMD
89 hedge funds and large institutions have $227M invested in iRadimed in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 6 closing their positions.
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
50% more capital invested
Capital invested by funds: $152M → $227M (+$75.3M)
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
13% more funds holding
Funds holding: 79 → 89 (+10)
1.81% more ownership
Funds ownership: 44.04% → 45.85% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
Top Sellers
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.89M |
| 2 |
RCMC
RK Capital Management (Colorado)
Denver,
Colorado
|
-$1.11M |
| 3 |
Renaissance Technologies
New York
|
-$498K |
| 4 |
Millennium Management
New York
|
-$491K |
| 5 |
Morgan Stanley
New York
|
-$401K |
IRMD Hedge Fund Activity: Q1 2023 in Review
89 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q1 2023, worth a combined $227M — up 50% from $152M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IRMD positions and 6 closed out — a net gain of 10 holders — while 32 added to existing stakes and 25 trimmed.
The largest buyer was Bares Capital Management, adding an estimated $1.66M. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $1.89M sold.
- 89 institutional investors held iRadimed (IRMD) as of Q1 2023, up from 79 in Q4 2022.
- Funds reported $227M of iRadimed stock for Q1 2023, up 50% quarter-over-quarter.
- 16 funds opened new iRadimed positions in Q1 2023 and 6 closed out, a net change of +10 holders.
- The largest iRadimed buyer in Q1 2023 was Bares Capital Management, an estimated $1.66M added.
- The largest iRadimed seller in Q1 2023 was Assenagon Asset Management, an estimated $1.89M sold.
Based on aggregated 13F filings for Q1 2023.